登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 19 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 19
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
- 研究中心北京医院Beijing Hospital北京医院页面
- 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
- 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
- 研究中心杭州市第一人民医院Hangzhou First People's Hospital杭州医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
- 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
- 研究中心苏州大学附属第二医院Second Affiliated Hospital of Soochow University苏州医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
- 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心天津市第一中心医院Tianjin First Central Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06521255,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
One of the histologies of DLBCL confirmed by participated sites below with,not otherwise specified;T-cell/histiocyte-rich large B-cell lymphoma;Epstein-Barr virus (EBV) positive DLBCL (EBV-positive DLBCL); Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse; Disease transformed from an earlier diagnosis of low-grade lymphoma into DLBCL with DLBCL treatment failure.
入选标准第 2 条
Existing or prior history of other malignant tumor within 3 years, except for those who have received curative treatment.
排除标准第 1 条
Prior exposure to anti-CD19 treatment, and (or) failed with gemcitabine plus platinum-based agent combination therapy.
排除标准第 6 条
Current toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, neutrophil, hemoglobin and platelets).
排除标准第 7 条
ECOG PS score of 0 to 2.
入选标准第 7 条
At least one measurable site of disease per CT or magnetic resonance imaging (the longest axis of the lymph node lesion is > 1.5 cm, and the longest diameter of the extra-nodal lesion is > 1.0 cm).
入选标准第 6 条
Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B or C infection.
排除标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06521255,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
18 Years and older. One of the histologies of DLBCL confirmed by participated sites below with,not otherwise specified;T-cell/histiocyte-rich large B-cell lymphoma;Epstein-Barr virus (EBV) positive DLBCL (EBV-positive DLBCL); Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse; Disease transformed from an earlier diagnosis of low-grade lymphoma into DLBCL with DLBCL treatment failure. Availability of tumor tissue biopsied post last line of therapy and prior to current study treatment for the patients enrolled in safety and tolerability stage. Relapsed/refractory (R/R) DLBCL, at least one (≥1) but no more than three (≤3) line of prior systemic therapies. Patients who have not received high dose therapy/stem cell transplantation (HDT/SCT) must be ineligible for HDT/SCT. At least one measurable site of disease per CT or magnetic resonance imaging (the longest axis of the lymph node lesion is > 1.5 cm, and the longest diameter of the extra-nodal lesion is > 1.0 cm). ECOG PS score of 0 to 2. Subject must have adequate organ functions, and the laboratory values comply with the protocol requirements. Life expectancy of ≥ 3 months. Informed consent before screening and can understand and comply with the requirements of the study.排除标准:Exclusion Criteria:
Existing or prior history of other malignant tumor within 3 years, except for those who have received curative treatment. Current or history of central nervous system (CNS) lymphoma. Known high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Primary mediastinal B-cell lymphoma. History of allogeneic stem-cell transplantation. Prior exposure to anti-CD19 treatment, and (or) failed with gemcitabine plus platinum-based agent combination therapy. Current toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, neutrophil, hemoglobin and platelets). Clinically significant cardiovascular disease or nervous system disease. History of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period. Uncontrolled systemic infection requiring parenteral intravenous anti-infective therapy. Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B or C infection.
引自 ClinicalTrials.gov, NCT06521255, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06521255,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。